CGTLive®’s Weekly Rewind – May 3, 2024
Review top news and interview highlights from the week ending May 3, 2024.
ODAC Supports MRD Endpoint in Accelerated Approval for Multiple Myeloma
The ODAC unanimously voted in favor of the use of minimal residual disease negativity.
FDA Activity Recap: April 2024 Features New Product Approval, 2 Expanded Indication Approvals, and More
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.
Around the Helix: Cell and Gene Therapy Company Updates – May 1, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Looking Forward to A Potential First Cell Therapy Approval for Sarcomas
John A. Charlson, MD, associate professor of medicine, Medical College of Wisconsin, discussed advantages of afami-cel for synovial sarcoma and other solid tumors.
TMZ γδ T-Cell Regimen May Have Potential in Treating Glioblastoma
A phase 1 trial evaluating INB-200 has shown a PFS benefit in treated participants.